Ultra-processed food found strongly linked to early onset Parkinson's
People who regularly eat ultra-processed food may be at a higher risk of developing early signs of Parkinson's disease than those who don't, a new study suggests.
Ultra-processed food includes mass-produced bread, crisps, cereals, and fizzy drinks which contain preservatives, artificial colours and flavours as well as additives like emulsifiers.
Previous studies have linked frequent consumption of ultra-processed food to health problems such as obesity, heart illness, cancer, and early death.
Now, a study published in the journal Neurology suggests that regularly eating ultra-processed food is strongly linked to early signs of Parkinson's disease, which could progress into more serious symptoms like tremors and slowed movement.
'Our research shows that eating too much processed food, like sugary sodas and packaged snacks, might be speeding up early signs of Parkinson's disease,' Xiang Gao, an author of the study from Fudan University in China, said.
'Eating a healthy diet is crucial as it has been associated with a lower risk of neurodegenerative diseases and the dietary choices we make today can significantly influence our brain health in the future.'
The study assessed 43,000 people with an average age of 48 who did not have Parkinson's initially. Their health status was tracked for 26 years with regular questionnaires and medical exams.
Researchers looked out for the participants' sleep behaviour, constipation, depressive symptoms, body pain, impairment in colour vision, excessive daytime sleepiness, and reduced ability to smell to determine if they had early signs of Parkinson's.
They also had the participants complete a food diary every two to four years, detailing what they ate and how often.
Researchers calculated each person's average daily intake of ultra-processed food and divided them into five categories on the basis of how much of it they ate.
The first group ate 11 or more servings of ultra-processed food per day on average and the lowest-ranked category fewer than three servings a day.
The first group had a 2.5-fold higher chance of having three or more early signs of Parkinson's disease compared to people consuming fewer than three servings a day, researchers found.
This was after adjusting for factors such as age, physical activity and smoking.
Researchers also found that eating more ultra-processed food was strongly linked to a greater risk for nearly all symptoms except constipation. 'Choosing to eat fewer processed foods and more whole, nutritious foods could be a good strategy for maintaining brain health,' Dr Gao said.
Citing a limitation of the study, researchers said the participants self-reported the amount of ultra-processed food they ate, meaning they might not have accurately remembered how much they ate.
'More studies are needed,' Dr Gao noted, 'to confirm our finding that eating less processed food may slow down the earliest signs of Parkinson's disease.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CNET
an hour ago
- CNET
I Optimized My Self-Care Routine Using AI. It Had Some Interesting Ideas
The term "self-care" may be one of the most overused buzz hyphenates on the internet. All sorts of activities can fall into the category of "self-care," casting a net wide enough to encompass everything from washing your face to finding ways to relax. Ironically, falling behind in your self-care activities can serve as a source of anxiety for the already stressed population, of which so many of us are well-worn card-carrying members, trying to quiet the riot inside our heads. Bubble bathing, face masking and attending trendy exercise classes in the pursuit of a better quality of life are common solutions, but keeping up with them is a whole separate battle. Here's how you can use AI to create a flexible, realistic self-care plan and keep yourself on track when you'd rather soothe via doom scrolling or consumption of substances that are not prepared, or conceived, with care in mind. Invest in feeling awesome Since the realm of self-care is so broad, using an AI tool to discover stuff that might enhance your calm with the push of a button can keep you focused. I used Gemini's Deep Research tool to give me a comprehensive list of products that claim to have self-care benefits instead of wading through wave after wave of targeted junk, or wondering which massager won't fly out of your hands when slicked up with calming essential oils. Deep Research was good for this one because I got a preview of the parameters under which the tool would create its findings, perfect when you need to be specific about exclusions like simple face wash. Deep Research allows for revisions on search parameters, no matter how creepy, before you start the results gathering process. Google Gemini / Screenshot by CNET This is not the primary use case of Deep Research, but when you're dealing with slippery essential oils, you can never have too much insight. Google Gemini / Screenshot by CNET Take a little look-see inside yourself Humans are notoriously lousy at unpracticed, unfocused introspection, but the cold, calculating zeroes and ones of an AI tool like ChatGPT can offer you an outside perspective on what you're capable of doing with any regularity in the self-care department. Provide an honest overview of your lifestyle, including any work, school or life commitments (like my hypothetical clown school in the example below), to give the tool the best possible chance at recommending strategies for self-care that keep you invested. ChatGPT / Screenshot by CNET Google Gemini / Screenshot by CNET When you can't keep an appointment to save your under-cared life A little self-care every once in a while is great, even if it's just sporadic, but what you really want for maximum relaxation impact is a ritual or at least a menu of activities designed to peak your well-being. ChatGPT gave me a breakdown of all the things I can do on a daily, weekly, monthly and yearly basis to take my self-care game to the next level over a gradual period of time, giving me seasonal self-care events to look forward to. The Winter schedule would be particularly useful if you're trying to make some positive changes for the new year. ChatGPT / Screenshot by CNET Self-care activities are best when they not only nourish your body and mind but also set your soul on fire. Give AI tools a chance to help you discover what gets you going, or if you're already aware, resist the urge to lie or be shy. BONUS: Anonymity and the ability to cast shame aside is one of the best things about using AI tools for private matters you might need to consult a human about, like a wellness coach or personal trainer. Letting your freak flag fly in the pursuit of happiness is a lot easier when you're unburdening yourself to a machine. You may have been holding back on starting a solid self-care routine activity you're embarrassed about because of what those other pesky humans might think. Screw 'em! The robot listens and doesn't judge. ChatGPT was more than up for the task. It also remembers whatever info you've fed into it already, so it matched up my clown schooling with some clown-themed activities: ChatGPT / Screenshot by CNET ChatGPT / Screenshot by CNET It must stay private.


Entrepreneur
2 hours ago
- Entrepreneur
Wipro Consumer Care – Ventures Makes First Foray into Pet Food with Investment in 'Goofy Tails'
This marks Wipro's third investment in 2025 and its 15th overall. You're reading Entrepreneur India, an international franchise of Entrepreneur Media. In a strategic expansion of its investment portfolio, Wipro Consumer Care – Ventures has announced its first investment in the pet food segment, backing New Delhi-based D2C pet nutrition brand Goofy Tails. The investment is part of a pre-series A round of over USD 1 million, bringing the total capital raised by Goofy Tails to USD 2 million. Founded in 2021 by Karan Gupta, Kartik, Kunal, and Ashish, Goofy Tails offers holistic pet nutrition including wholesome meals, freeze-dried foods, supplements, and treats. The products, formulated by veterinarians and nutritionists, are made from clean, 100% natural ingredients — free from gluten and preservatives, and designed for maximum bioavailability. Sumit Keshan, Managing Partner at Wipro Consumer Care – Ventures, said, "We are glad to partner with Goofy Tails, who are passionately addressing key gaps in India's pet food market. With pets increasingly becoming family, there is a growing demand for high quality, nutritious, and innovative pet food products. The founding team's deep expertise and strong execution gives us confidence in their potential." Goofy Tails claims to have already served over two lakh pets and sells through major online marketplaces, quick commerce platforms, and its own website. Karan Gupta, Co-founder of Goofy Tails, remarked, "Partnering with Wipro Consumer Care – Ventures is a significant milestone for us. This investment will not only help us scale and reach more pet parents across India but also accelerate R&D and new product innovation – further strengthening our mission." This marks Wipro's third investment in 2025 and its 15th overall. With this, the company has fully deployed Fund I and will now activate its INR 250 crore Fund II, continuing to focus on digital-first consumer brands across India and Southeast Asia.


Medscape
2 hours ago
- Medscape
Year-Long Methotrexate Not Helpful for Inflammatory Knee OA
Compared with placebo, low-dose methotrexate administered weekly at doses up to 15 mg for 52 weeks did not relieve knee pain or reduce the size of effusion-synovitis in patients with inflammatory knee osteoarthritis (OA). METHODOLOGY: Researchers in China conducted a multicenter, clinical trial between July 2019 and January 2023 to examine whether low-dose methotrexate can reduce knee pain and effusion-synovitis in knee OA. They included 215 patients (mean age, 60.6 years; 89% women) with inflammatory knee OA and effusion-synovitis who were randomly assigned to receive either methotrexate or placebo, with weekly 5 mg folic acid supplementation given 1 day after treatment. Participants continued their regular medications (except corticosteroids and anti-synovitis drugs), did not take trimethoprim, and avoided alcohol during the trial. Primary outcomes were changes in knee pain on the visual analog scale (VAS) and inflammation measured by the effusion-synovitis maximal area on MRI over 52 weeks. Secondary outcomes were assessment of pain, stiffness, and physical function; changes in infrapatellar fat pad signal intensity; and evaluation of response to the assigned treatment. TAKEAWAY: At week 52, no significant difference was found between methotrexate and placebo groups in terms of VAS pain and effusion-synovitis maximal area (between-group difference, 0.3 mm; 95% CI, -6.7 to 7.3 mm and 0.1 cm 2 ; 95% CI, -0.8 to 1.0 cm 2 , respectively). ; 95% CI, -0.8 to 1.0 cm , respectively). No significant differences were observed between the two groups in terms of any of the prespecified secondary outcomes. The frequency of experiencing at least one adverse event was comparable between the methotrexate and placebo groups (29.6% and 24.3%, respectively); however, elevated concentrations of liver enzymes were more common in the methotrexate group. IN PRACTICE: 'Given the lack of efficacy of MTX [methotrexate] across knee OA studies and the known potential adverse events, it is not recommended for the treatment of painful, inflammatory knee OA. We now need to focus our attention on treatments that can both inhibit joint inflammation and stimulate chondrocytes within the cartilage to synthesize replacement matrix. The future of pharmaceuticals for knee OA needs to move past MTX,' Nancy E. Lane, MD, UC Davis Health, Sacramento, California, wrote in an accompanying editorial. SOURCE: This study was led by Zhaohua Zhu, PhD, Zhujiang Hospital, Southern Medical University, Guangzhou, China. It was published online on June 2, 2025, in JAMA Internal Medicine . LIMITATIONS: This study was conducted during COVID-19 shutdowns, which delayed recruitment and potentially increased loss to follow-up and nonadherence rates. The findings may not be fully generalizable because most participants were women, and racial and ethnic diversity was limited. The relatively small number of participants in each subgroup may have limited the ability to detect significant benefits in specific populations. DISCLOSURES: This study received funding from the National Key Research and Development Program of China, the National Natural Science Foundation of China, and the Clinical Research Startup Program of Southern Medical University. One author reported providing consulting advice on scientific advisory boards for various pharmaceutical companies outside the submitted work.